Ascletis Pharma Inc. is a biotechnology company engaged in the research, development, and production of pharmaceutical products, with a primary focus on therapeutics for metabolic diseases. The company utilizes proprietary technologies, including Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), the Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT), to develop small molecule and peptide drug candidates. Its pipeline includes lead programs such as ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes, and various fixed-dose combinations involving GLP-1R, GIPR, and amylin receptor agonists. The company also explores indications in immune diseases and other exploratory areas. Ascletis Pharma Inc. is listed on the Main Board of the Stock Exchange under Chapter 18A of the Listing Rules.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage ascletis.com
Sector Healthcare IR page ascletis.com
Tags
metabolic diseases, glp-1r agonists, peptide therapeutics, small molecules, obesity, diabetes, drug discovery, oral formulations, ASC30, ASC30_48FDC, ASC30_48_39FDC, ASC39, ASC30_39FDC, ASC36, ASC35, ASC36_35FDC, ASC37, ASC36_37FDC, AISBDD, ULAP, POTENT, Ascletis BioScience, Ascletis Pharmaceuticals, Ascletis Pharma (China), Ascletis Biopharma, Ascletis Xinnuo Medicine, Gannex Pharma, Gannex LLC, ASCLETIS (AUSTRALIA) PTY LTD, SoundRidge Pharmaceuticals (Hong Kong) Co. Limited, AP11 Limited, PowerTree
Press page ascletis.com/news

Metrics

Valuation  
Market cap HK$ 4.62B
Market cap (USD) $ 588.78M
P/E -6.64
PEG —
P/BV 1.60
P/S —
P/OCF -6.87
P/FCF —
Dividend yield —
Turnover / mcap 0.10%
Returns  
ROE -18.5%
ROI -18.6%
ROIC -13.9%
Profit margin -17,745.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 2.028M 1.283M 56.596M 54.09M 76.876M 35.001M 173.443M 166.325M 53.202M
Net profit -359.88M -300.936M -144.715M -314.843M -199.017M -209.241M -95.969M -7.258M -53.935M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 10.94 — — 3.61 3.44 3.78 3.91 6.87 —
Price performance 12m — — — 0 -0.02 -0.03 -0.45 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Ascletis Pharma Inc. (ticker 1672), listed in Hong Kong.

ETFs Holding Ascletis Pharma Inc.

ETF Weight in ETF Shares Market value As of
OZEM 3.21% 3,227,000 $ 1.795M Nov 17, 2026
AVSE 0.01% 40,000 $ 21.635K Nov 16, 2026